News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Patrick D. Mauldin, PhD

Articles by Patrick D. Mauldin, PhD

The Changing Healthcare Market and How It Has Influenced the Treatment of Cardiovascular Disease - Part I

ByEdmund R. Becker, PhD,Douglas C. Morris, MD,Steven D. Culler, PhD,Patrick D. Mauldin, PhD,Leslee J. Shaw, PhD,J. David Talley, MD,Will

September 1st 1999

The Changing Healthcare Market: Outlook for the Future of Cardiovascular Disease Treatment - Part II

ByEdmund R. Becker, PhD,Douglas C. Morris, MD,Steven D. Culler, PhD,Patrick D. Mauldin, PhD,Leslee J. Shaw, PhD,J. David Talley, MD,Will

September 1st 1999

Economic Winners and Losers After Introduction of an Effective New Therapy Depend on the Type of Payment System

ByWilliam S. Weintraub, MD,Christi D. Warner, PhD,Patrick D. Mauldin, PhD,Edmund R. Becker, PhD,Daniel Gomes, MPH,John Cook, PhD,Andrzej

May 1st 1997

Determinants of Hospital Charges and Costs in Acute Myocardial Infarction: A Report from the Myocardial Infarction Cost Study (MICS) Group

ByWilliam S. Weintraub, MD,Patrick D. Mauldin, PhD,J. David Talley, MD,George A. Diamond, MD,John Merlino, MD,Joseph Lindsay, MD,Monty M. Bodenheimer, MD,Samuel DeMaio, MD,Lloyd W. Klein, MD,Da

December 1st 1996

The Influence of New Devices on the Costs of Interventional Procedures

ByWilliam S. Weintraub, MD,Ron Waksman, MD,Jim Benard, RN, MS,Edmund R. Becker, PhD,Patrick D. Mauldin, PhD,Ziyad M. B. Ghazzal, MD,John

October 1st 1996

Determinants of Hospital Charges and Costs in Acute Myocardial Infarction: A Report from the Myocardial Infarction Cost Study (MICS) Group

ByWilliam S. Weintraub, MD,Patrick D. Mauldin, PhD,J. David Talley, MD,George A. Diamond, MD,John Merline, MD,Joseph Lindsay, MD,Monty M. Bodenheimer,Samuel DeMaio, MD,Lloyd W. Klein, MD,David Faxon, MD,William W. O'Neill, MD,David Williams, MD,Russell Ivanhoe, MD,Michael Stillabower, MD,Andrew Buda, MD,Jonathon Halperin, MD,Robert Vogel, MD

September 1st 1996

Latest Updated Articles

Trending on AJMC

5 August FDA Approvals Marked by Novelty, Pushback

Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD

Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD

Cross-Trial Vitiligo Data: What Payers Can and Can't Compare

Counseling Vitiligo Patients on Time to Repigmentation